ATLANTA-(BUSINESS WIRE)–Geneka Inc. (“Geneca”), the first company to produce drugs with the same effective active ingredients used by big pharma – but without any artificial fillers – is appealing a wrongful, adverse decision by the Better Business Bureau’s National Advertising Division (“NAD”). The erroneous NAD decision stems from a challenge by Johnson & Johnson Consumer, Inc. (“Johnson & Johnson”) which contested Geneca’s claims regarding its own ingredients versus competitors’ ingredients.
The following statements and opinions are attributed to Geneka Inc.
Johnson & Johnson, among other competitors, doesn’t want consumers to know the truth about conventional OTC pain relievers and fever relievers. It’s true that just because the FDA approves an ingredient to be used in low doses, that doesn’t mean it’s safe to use in high doses. The truth is, none of us know the long-term impact of all the various artificial sweeteners and other ingredients our loved ones ingest. It is true that the European Union banned titanium dioxide in food last year, but it is still present in conventional OTC medicines.1 It is true that certain countries require warning labels on food products for children that contain artificial colors.2 It’s true that pediatricians would prefer Geneka Kids’ pain and fever reliever over Children’s Tylenol for their children, based on the respective ingredients.3
NAD’s recommendations were wrong from start to finish. First, Geneka has the right to tell the public that pediatricians prefer Geneka Kids’ pain and fever reliever for their own children, based on ingredients, over similar Tylenol Children’s products. Geneca commissioned a national survey—conducted by a reputable research company—of pediatricians with children ages 2 to 11. The survey asked pediatricians to look at the ingredients contained in Geneka Kids’ Pain & Fever, as well as the ingredients of all versions of children’s Tylenol Liquid Pain + Fever, and answer one question: “Which product would you prefer for your children?” The results overwhelmingly showed that the vast majority of pediatricians preferred Geneca’s product. Although we disagree with the NAD’s conclusion, we are pleased that the NAD ruled that based on the survey results, Geneka can advertise that pediatricians prefer Geneka Kids’ Pain & Fever’s ingredients over those in Children’s Tylenol comparable products.
Additionally, the NAD erred in its ruling regarding Geneca’s educational advertising addressing the factual attributes of Tylenol’s ingredients. NAD believes that by highlighting such facts, Geneca could lead a person to believe that medicines containing such ingredients could be harmful to them. NAD’s thinking on this seemed to be based on the facts that the FDA allows these ingredients in drugs and that Geneca has not submitted any scientific evidence illustrating that such ingredients can be harmful to humans. NAD simply made a mistake in the characterization of the record. Geneca has indeed provided scientific evidence from highly reputable medical researchers showing that some of the inactive ingredients commonly used in our medications, which are permitted by the FDA, may be harmful to humans.4
Geneca stands behind each of its contested claims and looks forward to appealing the NAD’s decision to the National Advertising Review Board.
Founded in 2016 by two dads with a mission to revolutionize the medical center, Geneka makes medicines with the same active ingredients that people need, but without artificial ones that don’t work. Geneca believes that people deserve the right choice. That’s why their business is built on a commitment to putting people first. All Geneka products are made according to the highest medical standards without artificial colors, common allergens or unnecessary inactive ingredients. It’s real medicine, cleaned up. With a commitment to innovation at every turn, Geneka was recently named to the prestigious Fast Company list of the world’s most innovative companies for 2022. Learn how Geneka puts people first, in everything they do, at Geneka.com.
1 Commission Regulation (EU) 2022/63 of January 14, 2022 amending Annexes II and III of Regulation (EC) no. 1333/2008 of the European Parliament and of the Council as regards the food additive titanium dioxide (E 171)  SL L 11/1
2 European Parliament. (July 7, 2008). Modernization of the rules on food additives and labeling of azo dyes [Press release]. https://vvv.europarl.europa.eu/RegData/presse/pr_info/2008/EN/03A-DV-PRESSE_IPR(2008)07-07(33563)_EN.pdf
3 FRC, Lieberman National Survey, Pediatrician Preferences, Spring, 2021.
4 Reker et al., “Inactive” Ingredients in Oral Medicines, Science Translational Medicine 11 eaau6753 (2019).; Yu and Guo, Noncaloric artificial sweeteners exhibit antimicrobial activity against bacteria and promote bacterial evolution of antibiotic tolerance, Journal of Hazardous Materials 433 (2022) 128840.